Over the next decade or more experts say pain treatment will look very different than it does today, with more effective care.
Author: Karen Weintraub, USA TODAY
America has a pain problem. How can we find relief?
To better understand America’s pain problem and what to do about it, USA TODAY spoke with more than 50 pain experts and people with chronic pain.
NFL players age faster than the rest of us. Harvard is researching what can be done.
A Harvard study finds NFL players age a decade faster than the general population and are suffering young from arthritis and high blood pressure.
Weight loss treatment is on the verge of transformation. It’s not there yet. Here’s why.
New medicines like Wegovy promise dramatic weight loss, but there’s a long way to go to make anti-obesity drugs accessible to those who need them.
Where did mpox go? Here’s what brought down cases of disease formerly known as monkeypox.
Cases of the disease formerly known as monkeypox are down as the Biden administration declares an end to the public health emergency.
Is Tylenol safe during pregnancy? Expert raises alarm about possible link to autism, ADHD.
Can you take Tylenol during pregnancy? A renowned epidemiologist cautions pregnant people that acetaminophen may be linked to autism or ADHD.
Thousands of babies and children are hospitalized by RSV every year. Why that could soon change.
Six drug companies are now developing RSV vaccines or antibodies, suggesting this year could be the last without adequate tools to fight the virus.
For patients with earliest stage of breast cancer, how much treatment is enough?
Doctors are getting better at figuring out who with the earliest stage of breast cancer needs aggressive treatment and who can get less care.
These rats have human cells in their brains. They may help scientists understand autism and schizophrenia.
Stanford researcher Sergiu Pașca’s experiments, published Wednesday in the journal Nature, are both significant and ethically challenging.
FDA approves Relyvrio, the first new ALS drug in five years. Patients had wanted it sooner.
The Food and Drug Administration on Thursday approved the use of Relyvrio to treat amyotrophic lateral sclerosis, more commonly known as ALS.